Agennix

Agennix is a publicly traded biopharmaceutical company that was founded in 1993. The company's primary focus is on developing innovative therapies for significant unmet medical needs, with the aim of enhancing both the duration and quality of life for seriously ill patients. Its leading program, talactoferrin, has shown efficacy in randomized, double-blind, placebo-controlled Phase 2 studies for non-small cell lung cancer and severe sepsis, and is currently undergoing Phase 3 clinical trials for non-small cell lung cancer. In addition to talactoferrin, Agennix is also involved in the clinical development of RGB-286638, a multi-targeted kinase inhibitor; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers. The company operates from its headquarters in Heidelberg, Germany, with additional operational sites in Martinsried/Munich, Germany; Princeton, New Jersey; and Houston, Texas. Agennix received a €76.00M Venture Round investment on 01 October 2010. With its focus on addressing unmet medical needs and promising pipeline of therapies, Agennix holds potential for growth and impact in the biopharma, biotechnology, healthcare, and pharmaceutical industries.